Valuation: Adocia

Market Cap 7.75Cr 8.91Cr 7.21Cr 6.62Cr 13Cr 850.84Cr 13Cr 85Cr 33Cr 423.58Cr 33Cr 33Cr 1.42TCr P/E 2026 *
-723x
P/E 2027 * 5.73x
Enterprise Value 4.76Cr 5.48Cr 4.43Cr 4.07Cr 7.69Cr 523.12Cr 7.81Cr 52Cr 21Cr 260.43Cr 21Cr 20Cr 873.27Cr EV / Sales 2026 *
18.9x
EV / Sales 2027 * 3.04x
Free-Float
95.03%
Yield 2026 *
-
Yield 2027 * -
1 day+1.17%
1 week+6.97%
1 month-2.54%
3 months-15.36%
6 months-33.72%
Current year-37.85%
1 week 3.83
Extreme 3.832
3.99
1 month 3.68
Extreme 3.68
4.33
Current year 3.68
Extreme 3.68
7.35
1 year 3.68
Extreme 3.68
11.4
3 years 3
Extreme 2.995
15.72
5 years 2.74
Extreme 2.745
15.72
10 years 2.74
Extreme 2.745
62.12
Manager TitleAgeSince
Chief Executive Officer 55 11/05/2023
Director of Finance/CFO - 23/09/2024
Chief Tech/Sci/R&D Officer - 01/12/2014
Director TitleAgeSince
Director/Board Member 55 19/04/2013
Chairman 80 24/02/2012
Director/Board Member 58 18/06/2013
Change 5-day change 1-year change 3-year change Capi.($)
+1.17%+6.97% - - 8.91Cr
+2.35%+2.74%+38.10%+71.29% 5.65TCr
-0.21%-7.38%+27.52%+61.15% 5.36TCr
-2.44%+1.40%-15.61%-15.45% 2.29TCr
-2.85%-7.78%-9.28%+345.55% 2.14TCr
+2.49%-0.92%+23.57%-13.14% 2.03TCr
+0.79%-1.06%+33.99%-31.95% 1.76TCr
+0.58%-5.88%+19.40%+527.50% 1.47TCr
+3.41%-6.61%+162.81%+278.22% 1.35TCr
-5.25%-4.23%+42.32%+170.15% 1.33TCr
Average +0.00%-3.79%+35.87%+154.81% 2.6TCr
Weighted average by Cap. +0.23%-2.96%+30.79%+116.84%

Financials

2026 *2027 *
Net sales 25.22L 29.01L 23.47L 21.55L 40.69L 28Cr 41.32L 2.77Cr 1.09Cr 14Cr 1.09Cr 1.07Cr 46Cr 3.54Cr 4.07Cr 3.29Cr 3.03Cr 5.71Cr 388.74Cr 5.8Cr 39Cr 15Cr 193.53Cr 15Cr 15Cr 648.94Cr
Net income -43.17L -49.66L -40.18L -36.89L -69.67L -47Cr -70.75L -4.74Cr -1.86Cr -24Cr -1.87Cr -1.82Cr -79Cr -4.43Cr -5.1Cr -4.13Cr -3.79Cr -7.15Cr -486.77Cr -7.26Cr -49Cr -19Cr -242.34Cr -19Cr -19Cr -812.6Cr
Net Debt -2.98Cr -3.43Cr -2.78Cr -2.55Cr -4.82Cr -327.72Cr -4.89Cr -33Cr -13Cr -163.15Cr -13Cr -13Cr -547.08Cr 3.02Cr 3.47Cr 2.81Cr 2.58Cr 4.87Cr 331.37Cr 4.95Cr 33Cr 13Cr 164.97Cr 13Cr 13Cr 553.18Cr
Logo Adocia
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2025, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram and BioChaperone Glucagon) and 4 preclinical-stage products (AdoShell® Islets, AdOral® Sema, AdoGel® Sema and BioChaperone® CagriSema).
Employees
73
Date Price Change
31/26/31 €3.990 +1.17%
30/26/30 €3.944 +0.36%
29/26/29 €3.930 +1.76%
28/26/28 €3.862 +0.78%
27/26/27 €3.832 +2.73%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.960EUR
Average target price
9.700EUR
Spread / Average Target
+144.95%

Quarterly revenue - Rate of surprise